Jade Biosciences Doses First Cohort In Phase 1 Healthy Volunteer Trial Of JADE101, A Novel Anti-APRIL Monoclonal Antibody For IgA Nephropathy

Jade Biosciences, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases, has announced that it has dosed the first group of participants in a Phase 1 clinical trial of JADE101 in healthy volunteers. JADE101 is an investigational monoclonal antibody that is designed to selectively block the activity of A Proliferation-Inducing Ligand (APRIL), a key driver in immunoglobulin A nephropathy (IgAN). 

By targeting APRIL, the therapy aims to offer a new treatment option for patients living with this chronic kidney disease. The Phase 1 study is a randomized, double-blind, placebo-controlled trial evaluating single ascending subcutaneous doses of JADE101 in healthy adults. The main objectives of the trial are to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. Jade Biosciences expects to report interim Phase 1 results in the first half of 2026.

Andrew King, Ph.D., Chief Scientific Officer and Head of R&D at Jade Biosciences, stated, “We believe the anti-APRIL class is poised to be the foundational treatment for patients with IgAN, an autoimmune kidney disease that leads to end-stage kidney disease over the lifetime of most patients. JADE101 has a differentiated preclinical profile, demonstrating femtomolar binding affinity to APRIL and deep and prolonged IgA reductions in non-human primates.”

He also added, “These properties could lead to potentially capturing the full efficacy of the anti-APRIL mechanism and offering the most convenient dosing schedule in the class-an important consideration for a lifelong disease that typically affects otherwise healthy young adults. Our interim healthy volunteer data are expected to be highly informative, providing readouts on APRIL and IgA biomarkers, and are anticipated to define dose and dosing interval selection for later-stage IgAN patient studies.”